These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33165862)

  • 1. A Genome Editing System for Therapeutical Targeting of Stem Cells.
    Frati G; Miccio A
    Methods Mol Biol; 2021; 2185():383-398. PubMed ID: 33165862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
    Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
    Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells.
    Wagenblast E; Azkanaz M; Smith SA; Shakib L; McLeod JL; Krivdova G; Araújo J; Shultz LD; Gan OI; Dick JE; Lechman ER
    Nat Commun; 2019 Oct; 10(1):4730. PubMed ID: 31628330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
    Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
    Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic base editing of human hematopoietic stem cells.
    Zeng J; Wu Y; Ren C; Bonanno J; Shen AH; Shea D; Gehrke JM; Clement K; Luk K; Yao Q; Kim R; Wolfe SA; Manis JP; Pinello L; Joung JK; Bauer DE
    Nat Med; 2020 Apr; 26(4):535-541. PubMed ID: 32284612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 genome editing in human hematopoietic stem cells.
    Bak RO; Dever DP; Porteus MH
    Nat Protoc; 2018 Feb; 13(2):358-376. PubMed ID: 29370156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.
    Gomez-Ospina N; Scharenberg SG; Mostrel N; Bak RO; Mantri S; Quadros RM; Gurumurthy CB; Lee C; Bao G; Suarez CJ; Khan S; Sawamoto K; Tomatsu S; Raj N; Attardi LD; Aurelian L; Porteus MH
    Nat Commun; 2019 Sep; 10(1):4045. PubMed ID: 31492863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
    DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE
    Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
    Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
    Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
    Brunetti L; Gundry MC; Kitano A; Nakada D; Goodell MA
    J Vis Exp; 2018 Apr; (134):. PubMed ID: 29708546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editing the immune system in vivo in mice using CRISPR/Cas9 ribonucleoprotein (RNP)-mediated gene editing of transplanted hematopoietic stem cells.
    Wang R; Graham S; Gao L; Tam J; Levesque MC
    Methods; 2021 Oct; 194():30-36. PubMed ID: 33422676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
    Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
    Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines.
    Martin Gonzalez J; Baudet A; Abelechian S; Bonderup K; d'Altri T; Porse B; Brakebusch C; Juliusson G; Cammenga J
    Genesis; 2018 Sep; 56(9):e23238. PubMed ID: 30010246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
    Mettananda S; Fisher CA; Hay D; Badat M; Quek L; Clark K; Hublitz P; Downes D; Kerry J; Gosden M; Telenius J; Sloane-Stanley JA; Faustino P; Coelho A; Doondeea J; Usukhbayar B; Sopp P; Sharpe JA; Hughes JR; Vyas P; Gibbons RJ; Higgs DR
    Nat Commun; 2017 Sep; 8(1):424. PubMed ID: 28871148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.